uyanikgil, yigit/0000-0002-4016-0522WOS: 000543649400001PubMed: 32515626Background:Human epidermal growth factor receptor 2 (HER2) is overexpressed in a subset of cancers including 25% of breast cancers. Since combination therapy consisting of multiple therapeutic approaches is considered a promising regimen, we examined combination treatment modalities in a xenograft model in Balb/c mice injected with 4T1-HER2 cells. We used HER2/neu-loaded bone marrow-derived dendritic cells (BM-DC's) along with anti-PD-L1 monoclonal antibody in a new combination immunotherapy model. Methods:The combination was composed of an active immunotherapy (i.e. BM-DC-based vaccine) designed to boost the immune response against target antigen and was augmented by u...
Objective: Breast cancer is responsible for most of the cancer-induced deaths in women around the wo...
To investigate the specific anti-breast cancer immune response induced by dendritic cells (DC) loade...
Therapeutic blockade of PD-1/PD-L1 signaling with monoclonal antibodies (mAbs) has shown clinical su...
Improvements in the use of traditional breast cancer therapies have improved the overall survival of...
Introduction: Given their relative simplicity of manufacture and ability to be injected repeatedly, ...
A significant proportion of human epidermal growth factor receptor 2 (Her2/ErbB2)-positive metastati...
Breast cancer is the most common cancer among women. Of all breast cancers cases, approximately 30 p...
Purpose: HER2/neu is frequently overexpressed in breast cancer. In a mouse model, vaccination with H...
In our previous studies, using a B cell vaccine (scFv-Her2), the targeting of tumor-associated antig...
Purpose:Treatments for metastatic human epidermal growth factor receptor 2 (HER2)-positive tumors ar...
Increasing evidence suggests that antibody-drug conjugates (ADCs) can enhance anti-tumor immunity an...
INTRODUCTION: Once metastasis has occurred, the possibility of completely curing breast cancer is un...
For cancer vaccines, the selection of optimal tumor-associated antigens (TAAs) that can maximize the...
INTRODUCTION: The availability of mice transgenic for the human HER2 gene (huHER2) and prone to the ...
13. Abstract fMudmum 200 Worda) (abstract should contain no proprietary or confidential information)...
Objective: Breast cancer is responsible for most of the cancer-induced deaths in women around the wo...
To investigate the specific anti-breast cancer immune response induced by dendritic cells (DC) loade...
Therapeutic blockade of PD-1/PD-L1 signaling with monoclonal antibodies (mAbs) has shown clinical su...
Improvements in the use of traditional breast cancer therapies have improved the overall survival of...
Introduction: Given their relative simplicity of manufacture and ability to be injected repeatedly, ...
A significant proportion of human epidermal growth factor receptor 2 (Her2/ErbB2)-positive metastati...
Breast cancer is the most common cancer among women. Of all breast cancers cases, approximately 30 p...
Purpose: HER2/neu is frequently overexpressed in breast cancer. In a mouse model, vaccination with H...
In our previous studies, using a B cell vaccine (scFv-Her2), the targeting of tumor-associated antig...
Purpose:Treatments for metastatic human epidermal growth factor receptor 2 (HER2)-positive tumors ar...
Increasing evidence suggests that antibody-drug conjugates (ADCs) can enhance anti-tumor immunity an...
INTRODUCTION: Once metastasis has occurred, the possibility of completely curing breast cancer is un...
For cancer vaccines, the selection of optimal tumor-associated antigens (TAAs) that can maximize the...
INTRODUCTION: The availability of mice transgenic for the human HER2 gene (huHER2) and prone to the ...
13. Abstract fMudmum 200 Worda) (abstract should contain no proprietary or confidential information)...
Objective: Breast cancer is responsible for most of the cancer-induced deaths in women around the wo...
To investigate the specific anti-breast cancer immune response induced by dendritic cells (DC) loade...
Therapeutic blockade of PD-1/PD-L1 signaling with monoclonal antibodies (mAbs) has shown clinical su...